Treatment for Achilles Tendinopathy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether sclerotherapy using a 25% dextrose and 1% lidocaine solution is an efficacious treatment for patients with chronic Achilles tendinopathy who have failed a home based, heavy load eccentric training program.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Calgary
• Collaborator: Sport Science Association of Alberta (SSAA)
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Adults 18 years of age and older with a minimum of 3 months of clinically determinant history and symptoms (pain) consistent with unilateral Achilles tendinopathy (enthesitis or mid-portion) as diagnosed by a sport medicine physician.

• Participants are not required to have tried other treatments, however, those who have tried other treatments (except injection treatments) including, but not restricted to, oral NSAIDs, topical NSAIDs, shoe modifications, and physical/athletic therapy will not be restricted from the study

• Provide informed consent for the controlled longitudinal study and RCT

Exclusion Criteria:

• Individuals with physical ailments precluding them from performing the eccentric training program

• Worker's Compensation Board (WCB) and elite athletes (varsity, national and professional level).

• Individuals younger than 18 years of age will be excluded from this trial due to the complicating factors of musculoskeletal immaturity and the lack of relevant research of Achilles tendinopathy and neovascular bundles in this population.

• Previous Achilles tendon rupture of the tendon in question

• Individuals that have received any type of injection in or around the Achilles tendon

• Known allergy to dextrose based sclerosing agent or other contraindications

• Known allergy to Lidocaine